about
Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafishStimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy.Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells.Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery.Facile Generation of Tumor-pH-Labile Linkage-Bridged Block Copolymers for Chemotherapeutic Delivery.Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy.Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.Responsive Nanocarriers as an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer.CD205-TLR9-IL-12 axis contributes to CpG-induced oversensitive liver injury in HBsAg transgenic mice by promoting the interaction of NKT cells with Kupffer cells.Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation.Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice.Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles.Tumor Acidity-Sensitive Polymeric Vector for Active Targeted siRNA Delivery.Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseasesOptimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammationThe effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticlesIn situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant toleranceEnhanced Primary Tumor Penetration Facilitates Nanoparticle Draining into Lymph Nodes after Systemic Injection for Tumor Metastasis InhibitionFacile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic DeliveryDevelopment of "CLAN" Nanomedicine for Nucleic Acid TherapeuticsNanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy
P50
Q33813508-FBE5B77D-50D9-4B78-BBAD-988D319AEBC1Q36821419-3D28E8AE-DB02-44CE-9852-A7FFAD93C491Q38759973-3D5A3BA5-EC32-4EC2-B3CE-18B408B8F792Q38788753-9CBB8888-282C-41F5-8D65-F313F8C989A5Q38804608-B3425323-529C-4300-A0D5-4F41EEFC50B7Q38900093-7817FFA9-C71E-4D45-8A9A-9F2819CF2237Q38934297-DB3580A7-0E0C-4C02-9BFE-4F58F5E004FFQ39232831-7A633954-33ED-4605-8781-3470E14E9BAFQ39866521-0C13F3ED-0749-4133-95AE-F75F84C34EB4Q40038348-A3B927E2-744B-4B4F-B069-9505D342D4B1Q41260378-55BEDB84-9224-4BBD-AD0A-EE65C26F8D04Q41548774-D5B94EF2-97CF-4E6D-8DFA-F55CCE22EBC7Q47190442-687A25E6-1A5F-4615-9EF3-3CC35A1491A1Q47620102-261E7FC4-BA6C-4DDF-BBC6-1E9BE1ED60C0Q54221324-E13471AD-425F-489B-8E83-3251832BCB2AQ57022694-36167CFF-7644-4F4C-ABBB-48B21D1E475AQ88558123-2B9F4A30-698B-429C-941B-8358BA175ACCQ90981529-9C98C190-4EE2-4FA3-AEC7-9B16DBAA9358Q91608943-E8107936-58D9-4F12-A255-BCE1346222DEQ92067265-BA3E4D2C-15E1-4F7F-9F1B-3586E00B1FC6Q92191349-A20C0ED1-F85B-43DD-8AE3-5F710E9721D0Q92446874-A8F03EF8-4B3F-424C-A32E-4E15B75E3369Q93179726-B6DC0AEB-AADA-4B5E-A19D-7FC82A1372B4
P50
description
researcher ORCID ID = 0000-0002-6291-5711
@en
wetenschapper
@nl
name
Cong-Fei Xu
@ast
Cong-Fei Xu
@en
Cong-Fei Xu
@nl
type
label
Cong-Fei Xu
@ast
Cong-Fei Xu
@en
Cong-Fei Xu
@nl
prefLabel
Cong-Fei Xu
@ast
Cong-Fei Xu
@en
Cong-Fei Xu
@nl
P31
P496
0000-0002-6291-5711